论文部分内容阅读
目的 通过观察终末期肝病模型(MELD)在终末期肝病预后预测中的作用,探讨其在临床的应用价值及人工肝支持系统在终末期肝病治疗中的效果。方法 43例病人随机分为治疗组与对照组,对其进行MELD评分,并对治疗组进行人工肝后评分,观察3个月后的死亡率。结果治疗组中4例治疗前MELD评分大于40分者,3个月死亡率为100％,17例治疗前评分30-40分者3个月死亡率为53％;对照组中6例MELD评分大于40分者,3个月死亡率为100％,16例治疗前评分30～40分者3个月死亡率为87％,与治疗组相比P<0.05。结论MELD评分可以引入临床推广应用,人工肝治疗MELD评分在30-40分的终末期肝病是安全有效的。
Objective To observe the role of end-stage liver disease (MELD) in predicting the prognosis of end-stage liver disease and to explore its clinical value and the effect of artificial liver support system in the treatment of end-stage liver disease. Methods Forty-three patients were randomly divided into treatment group and control group. MELD score was applied to the treatment group and artificial liver post-treatment score was given to the treatment group. Mortality after 3 months was observed. Results In the treatment group, the MELD score of 4 cases before treatment was more than 40 points, the 3-month mortality rate was 100%, 17 cases of pre-treatment score 30-40 points 3-month mortality rate was 53%; control group, 6 cases MELD score More than 40 points, 3 months mortality was 100%, 16 cases before treatment score of 30 to 40 were 3 months mortality was 87%, compared with the treatment group P <0.05. Conclusion MELD score can be introduced into clinical application. Artificial liver is safe and effective in treating end-stage liver disease with MELD score of 30-40.